Skip directly to content

Minimize RSR Award Detail

Research Spending & Results

Award Detail

Awardee:MYTIDE THERAPEUTICS, INC.
Doing Business As Name:MYTIDE THERAPEUTICS, INC.
PD/PI:
  • Dale A Thomas
  • (207) 659-4206
  • dale@mytide.io
Award Date:12/13/2019
Estimated Total Award Amount: $ 225,000
Funds Obligated to Date: $ 269,964
  • FY 2020=$269,964
Start Date:01/01/2020
End Date:08/31/2020
Transaction Type:Grant
Agency:NSF
Awarding Agency Code:4900
Funding Agency Code:4900
CFDA Number:47.041
Primary Program Source:040100 NSF RESEARCH & RELATED ACTIVIT
Award Title or Description:SBIR Phase I: Solid Phase Slug Flow (SPSF) for Drug Discovery
Federal Award ID Number:1938756
DUNS ID:116814346
Program:SBIR Phase I
Program Officer:
  • Alastair Monk
  • (703) 292-4392
  • amonk@nsf.gov

Awardee Location

Street:75 KNEELAND St FL 14
City:BOSTON
State:MA
ZIP:02111-1901
County:Boston
Country:US
Awardee Cong. District:07

Primary Place of Performance

Organization Name:Mytide therapeutics
Street:75 Kneeland st
City:boston
State:MA
ZIP:02111-1901
County:Boston
Country:US
Cong. District:07

Abstract at Time of Award

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to rapidly enable new therapeutically relevant molecules currently impractical to manufacture with conventional techniques. Peptides represent a growing subset of the therapeutics market: there are about 68 currently approved peptide treatments; ~140 peptide treatments in clinical trials and another 500 peptide treatments in the preclinical stage, representing a $21 B market growing to $44 B by 2025. While peptides therapeutics are known for indications such as oncology, cardiovascular disease, and metabolic disease, recent interest in personalized peptide therapeutics has grown. Currently, peptides take weeks to synthesize and are tremendously resource-intensive, costing hundreds to thousands of dollars for a few milligrams of product. These high costs and long lead times severely limit the number of molecules a researcher can test in a given period of time, representing the primary bottleneck in peptide therapeutic innovation. Faster access to these potentially therapeutic relevant molecules will accelerate discovery of new therapeutics. This Small Business Innovation Research (SBIR) Phase I project overcomes the major bottlenecks of peptide manufacturing. The Rapid Automated Computation, Coupling, Cleavage, and Chromatography Execution (RAC4E) Platform produces high purity custom peptides. However, to further extend the ability to control process conditions and achieve real-time process optimization, we propose developing solid-phase slug flow (SPSF) coupling, using advanced engineering and machine learning solutions to generate purity in molecules during synthesis, enabling optimization of the peptide chain in real-time. Combining these solutions will allow the production of peptides both faster and at longer lengths, as well as dramatically reducing the need for downstream purification. Once fully implemented, the RAC4E platform with SPSF coupling will produce peptide libraries at a speed and purity that will significantly increase the density of biological screening data serving as machine learning inputs. The platform will be later be scaled into a cGMP manufacturing environment, accelerating the rate of entry for novel peptide therapeutics into the clinic. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

For specific questions or comments about this information including the NSF Project Outcomes Report, contact us.